Máj- és epeúti rák: vizsgálatok itt: Kína
621 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleClinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
- Where
- Hangzhou
- Életkor
- 18 év to 80 év
- People
- 12
- Run by
- Zhejiang University
See details and how to joinNCT06676982 - 2. fázisTaking peopleAn Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 300
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07282262 - Korai 1. fázisTaking peopleA Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- Shanghai Juncell Therapeutics
See details and how to joinNCT05098197 - 2. fázisTaking peoplePembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 60
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT06230471 - 2. fázisTaking peopleTuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 45
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07267078 - No phaseTaking peopleMechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07263217 - 2. fázisNot yet taking people in KínaIparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 29
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07263360 - 3. fázisTaking peopleInfusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 262
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06172205 - 1/2. fázisTaking peopleStudy of GV20-0251 in Participants With Solid Tumor Malignancies
- Where
- Beijing, Shanghai
- Életkor
- 18 év and over
- People
- 350
- Run by
- GV20 Therapeutics
See details and how to joinNCT07070518 - 1. fázisTaking peopleHRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 12
- Run by
- Shanghai Ruiliyuan Biotechnology Co., Ltd.
See details and how to joinNCT06515314 - 2. fázisTaking peopleICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 300
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07157969 - 2. fázisTaking peopleStudy to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
- Where
- Beijing, Shenyang, Taiyuan, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07239245 - 1. fázisTaking peopleA Study of GV20-0251 in Advanced or Refractory Solid Tumors
- Where
- Chengdu
- Életkor
- 18 év and over
- People
- 10
- Run by
- West China Hospital
See details and how to joinNCT07106827 - No phaseTaking peopleStudy on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 33
- Run by
- Sir Run Run Shaw Hospital
See details and how to joinNCT07243691 - 2. fázisTaking peopleDalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Sun Yat-sen University
See details and how to joinNCT07238881 - 2. fázisNot yet taking people in KínaA Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
- Where
- Hefei, Shanghai
- Életkor
- 18 év and over
- People
- 60
- Run by
- Broadenbio Ltd., Co.
See details and how to joinNCT07239986 - No phaseTaking peopleDeep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 300
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07235410 - 2. fázisTaking peopleAtezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 55
- Run by
- Sun Yat-sen University
See details and how to joinNCT05751343 - No phaseNot yet taking people in KínaDosimetric Differences and Clinical Significance Analysis Between Body Gamma Knife and VMAT Radiotherapy for Primary Liver Cance
- Where
- Chifeng
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Chifeng Tumor Hospital
See details and how to joinNCT07211815 - No phaseNot yet taking people in KínaA Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 270
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07208526 - 2. fázisTaking peopleNeoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
- Where
- Fuzhou
- Életkor
- 18 év to 75 év
- People
- 33
- Run by
- Yongyi Zeng
See details and how to joinNCT06349317 - 2. fázisTaking peopleNeoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 39
- Run by
- Sun Yat-sen University
See details and how to joinNCT06467799 - 2. fázisTaking peopleSystemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Sun Yat-sen University
See details and how to joinNCT07192185 - 2. fázisNot yet taking people in KínaAdebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
- Where
- Shenzhen
- Életkor
- 18 év and over
- People
- 47
- Run by
- Song Peng
See details and how to joinNCT07192848 - 2/3. fázisTaking peopleSingle-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Zhujiang Hospital
See details and how to joinNCT06644937